Advertisement

Topics

Latest "GeneCentric Therapeutics, Inc." News Stories

18:28 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "GeneCentric Therapeutics, Inc." found in our extensive news archives from over 250 global news sources.

More Information about GeneCentric Therapeutics, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about GeneCentric Therapeutics, Inc. for you to read. Along with our medical data and news we also list GeneCentric Therapeutics, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of GeneCentric Therapeutics, Inc. Companies for you to search.

Showing "GeneCentric Therapeutics" News Articles 1–25 of 8,200+

Tuesday 19th February 2019

$MRTX Announces The Appointment Of Faheem Hasnain As Chairman Of The BOD https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-the-appointment-of-faheem-hasnain-as-chairman-of-the-board-of-directors-300798231.html …

$MRTX Announces The Appointment Of Faheem Hasnain As Chairman Of The BOD https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-the-appointment-of-faheem-hasnain-as-chairman-of-the-board-of-directors-300798231.html …


Gamida Cell and Editas Medicine Partner to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, to evaluate the potential use of Editas Medicine’s CRISPR technology to edit NAM-NK cells, which are natural killer cells that have been expanded using Gamida Cell’s proprietary nicoti...

D2 Agonist – Pipeline Insight, 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “D2 Agonist – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. D2 Agonist – Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across D2 Agonist development. The … Continue reading →


GABAB Agonist – Pipeline Insight, 2019 by Developmental Stage, Associated Indications, Route of Administration and Molecule Type – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “GABAB Agonist – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. GABAB Agonist – Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across GABAB Agonist development. The … Continue reading →

CRF1 Receptor Antagonist – Pipeline Insight, 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CRF1 Receptor Antagonist – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. CRF1 Receptor Antagonist – Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across CRF1 Receptor … Continue reading →...

Cardiol Featured on Market Call

Cardiol Therapeutics Inc. (TSX:CRDL), a biotechnology company developing proprietary formulations that will treat life-threatening diseases, was featured on BNN Bloomberg's Market Call with Robert McWhirter. The post Cardiol Featured on Market Call appeared first on Investing News Network.

Shield Therapeutics (STX) - Fortified for growth

Edison Investment Research - Pharmaceuticals & healthcare - Shield Therapeutics: Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulation of iron positioned for the treatment of iron deficiency (ID) with or without anaemia. In 2018, out-licensing Feraccru to Norgine re-established an active salesforce in core EU5 territories and provided...

Sage Therapeutics, Inc. (SAGE) CEO Jeff Jonas on Q4 2018 Results - Earnings Call Transcript

Spark Therapeutics. (ONCE) CEO Jeffrey Marrazzo on Q4 2018 Results - Earnings Call Transcript

Helsinn invests €1 million in Gain Therapeutics

Swiss company will use the funding to address lysosomal storage disorders, CNS indications and additional diseases

Bryan Garnier sets 155p fair value target on Summit Therapeutics, offering around 550% upside

The analysts said "we have established a fair value for Summit which we believe more accurately reflects its fundamental value than the current share price of 24p”

$PTX Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management. Files for chapter 11 https://globenewswire.com/news-release/2019/02/19/1734397/0/en/Pernix-Therapeutics-Holdings-Inc-Enters-into-Asset-Purchase-Agreemen

$PTX Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management. Files for chapter 11 https://globenewswire.com/news-release/2019/02/19/1734397/0/en/Pernix-Therapeutics-Holdings-Inc-Enters-into-Asset-Purchase-Agreement-with-Certain-Funds-Managed-by-Highbridge-Capital-Management.html …

BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences

BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF) (OTCQB:BCTXF) ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announces it has been selected to present a poster at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, held February 28–March 2, 2019, in San Francisco, California. The post BriaCell to ...

Sarepta Therapeutics - Is A Brief Stint At $190 A Share In The Cards For The Near Future?

Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors

Experienced Biotech Executive Brings More Than 30 Years of Pharmaceutical and Biotechnology Experience to Genprex Genprex, Inc. (NASDAQ: GN

$NVUS Doses First Patients in Phase 2a Trial of OP0201 https://www.businesswire.com/news/home/20190219005110/en/Novus-Therapeutics-Doses-Patients-Phase-2a-Trial …

$NVUS Doses First Patients in Phase 2a Trial of OP0201 https://www.businesswire.com/news/home/20190219005110/en/Novus-Therapeutics-Doses-Patients-Phase-2a-Trial …

$CBAY Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis. Twelve-week topline liver fat data, using MRI-PDFF, expected 2Q 2019 https://finance.yahoo.com/news/cymabay-therapeutics-announces-early-enro

$CBAY Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis. Twelve-week topline liver fat data, using MRI-PDFF, expected 2Q 2019 https://finance.yahoo.com/news/cymabay-therapeutics-announces-early-enrollment-130000420.html …

Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first patients in a phase 2a trial of OP0201, the company’s lead product candidate being developed for otitis media. “We are pleased to ...

Fusion Pharma Announces First Patient Dosing in a Phase 1 Clinical Trial of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumors

Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), today announced that the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors. "The entire Fusion team takes tremendous p...

4D Molecular Therapeutics Expands Leadership Team with Appointments and Promotions of Key Executives

Company adds manufacturing and quality expertise and broad financial, operational and legal experience with the appointments of Fred Kamal, PhD as chief technical officer and head of regulatory and quality and of August Moretti as chief financial officer Company announces promotions of Peter Francis, MD, PhD to chief medical...

Pioneering Gyroscope Therapeutics Aims To Develop One-Time Gene Therapy For AMD

Gyroscope Therapeutics, which aims to develop genetically defined therapies for a range of eye diseases, has begun dosing in a...    

$ORPN Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics. Unconditional payment of $3.5M Contingent payment of up to additional $17M plus royalties https://globenewswire.com/news-release/2019/02/19/1734172/0/en/Bioblast-P

$ORPN Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics. Unconditional payment of $3.5M Contingent payment of up to additional $17M plus royalties https://globenewswire.com/news-release/2019/02/19/1734172/0/en/Bioblast-Pharma-Announces-Sale-of-its-Trehalose-Clinical-Development-Programs-to-Seelos-Therapeutics.html …

$ONCE Reports 2018 Financial Results and Recent Business Progress https://finance.yahoo.com/news/spark-therapeutics-reports-2018-financial-123000828.html …

$ONCE Reports 2018 Financial Results and Recent Business Progress https://finance.yahoo.com/news/spark-therapeutics-reports-2018-financial-123000828.html …

CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement $CRSP https://finance.yahoo.com/news/crispr-therapeutics-stridebio-expand-exclusive-120000518.html …

CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement $CRSP https://finance.yahoo.com/news/crispr-therapeutics-stridebio-expand-exclusive-120000518.html …

Anthrax Global Clinical Trials Review, H2, 2018 [Report Updated: 31102018] Prices from USD $2500

Anthrax Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Anthrax Global Clinical Trials Review, H2, 2018" provides an overview of Anthrax clinical trials scenario. This report provides top line data relating to the clinical trials on Anthrax. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The r...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks